Literature DB >> 15206027

Challenges in the management of infantile factor H associated hemolytic uremic syndrome.

Guido Filler1, Seetha Radhakrishnan, Lisa Strain, Andrew Hill, Greg Knoll, Timothy H Goodship.   

Abstract

We describe a 1-year old with four episodes of recurrent hemolytic uremic syndrome (HUS). Family history suggested an autosomal dominant mode of inheritance. Factor H concentrations in the blood were normal in the affected family members. Mutation screening in the human complement factor H gene ( HF-1) revealed a novel mutation in exon 23 (c.3546_3581dup36). The HF-1 gene encodes complement factor H and the mutation leads to the insertion of 12 additional amino acids after codon 1176 in factor H. The recurrent HUS responded to plasma infusions and renal function improved from a glomerular filtration rate of 21 to 50 ml/min per 1.73 m(2). The infusions of fresh-frozen plasma were necessary at once-weekly intervals at a dose of 40-45 ml/kg in order to maintain remission and resulted in significant hyperproteinemia. This was addressed by intermittent plasma exchange through an arterio-venous fistula. The prognosis and therapeutic dilemmas are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15206027     DOI: 10.1007/s00467-004-1526-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  19 in total

Review 1.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings.

Authors:  N Banatvala; P M Griffin; K D Greene; T J Barrett; W F Bibb; J H Green; J G Wells
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

Review 3.  Pathophysiology and management of thrombotic microangiopathies.

Authors:  P Ruggenenti; G Remuzzi
Journal:  J Nephrol       Date:  1998 Nov-Dec       Impact factor: 3.902

4.  Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.

Authors:  Angela Gerber; Antje H Kirchhoff-Moradpour; Silke Obieglo; Matthias Brandis; Michael Kirschfink; Peter F Zipfel; Judith A Goodship; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

5.  Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.

Authors:  Anna Richards; Elizabeth J Kemp; M Kathryn Liszewski; Judith A Goodship; Anne K Lampe; Ronny Decorte; M Hamza Müslümanoğlu; Salih Kavukcu; Guido Filler; Yves Pirson; Leana S Wen; John P Atkinson; Timothy H J Goodship
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

6.  Atypical (non-diarrhea-associated) hemolytic-uremic syndrome in childhood.

Authors:  M M Fitzpatrick; M D Walters; R S Trompeter; M J Dillon; T M Barratt
Journal:  J Pediatr       Date:  1993-04       Impact factor: 4.406

7.  Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome.

Authors:  A Gianviti; A Perna; A Caringella; A Edefonti; R Penza; G Remuzzi; G Rizzoni
Journal:  Am J Kidney Dis       Date:  1993-08       Impact factor: 8.860

Review 8.  Plasmapheresis. Technical aspects and indications.

Authors:  François Madore
Journal:  Crit Care Clin       Date:  2002-04       Impact factor: 3.598

9.  High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome.

Authors:  Paul Coppo; Annette Bussel; Sabine Charrier; Christophe Adrie; Lionel Galicier; Emmanuelle Boulanger; Agnès Veyradier; Thierry Leblanc; Corinne Alberti; Elie Azoulay; Jean-Roger Le Gall; Benoît Schlemmer
Journal:  Medicine (Baltimore)       Date:  2003-01       Impact factor: 1.889

10.  Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula?

Authors:  Guido Filler; Nathalie Lepage
Journal:  Pediatr Nephrol       Date:  2003-08-13       Impact factor: 3.714

View more
  14 in total

Review 1.  Tandem hemodialysis and plasma exchange.

Authors:  Guido Filler; William F Clark; Shih-Han S Huang
Journal:  Pediatr Nephrol       Date:  2013-09-11       Impact factor: 3.714

2.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

3.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

Review 4.  Atypical haemolytic uraemic syndrome and mutations in complement regulator genes.

Authors:  Marie-Agnès Dragon-Durey; Véronique Frémeaux-Bacchi
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

5.  Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.

Authors:  Jon Jin Kim; Tim H J Goodship; Jane Tizard; Carol Inward
Journal:  Pediatr Nephrol       Date:  2011-06-30       Impact factor: 3.714

Review 6.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 7.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

Review 8.  The Genetics of Ultra-Rare Renal Disease.

Authors:  Melissa Muff-Luett; Carla M Nester
Journal:  J Pediatr Genet       Date:  2016-02-23

9.  Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations.

Authors:  Anne-Laure Lapeyraque; Eric Wagner; Véronique Phan; Marie-José Clermont; Aïcha Merouani; Véronique Frémeaux-Bacchi; Timothy H J Goodship; Pierre Robitaille
Journal:  Pediatr Nephrol       Date:  2008-04-19       Impact factor: 3.714

10.  Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options.

Authors:  Sudarsana De; Aoife M Waters; Audrey O Segal; Agnes Trautmann; Elizabeth A Harvey; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2009-10-24       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.